. Although the exact timeline of disease progression has yet to be determined, an important proportion of this window could be situated before arthritis becomes clinically evident.
Current therapies for RA are effective in suppressing inflammation, but their ability to modify disease persistence is limited 5 . Retrospective nested case-control studies have revealed that RA-related autoantibodies and markers of systemic or local subclinical inflammation can be present months or years before diagnosis [6] [7] [8] [9] [10] [11] [12] , demonstrating that the disease process is evolving long before the disease becomes clinically detectable. On the basis of current understanding of RA aetiopathogenesis, the EULAR study group for risk factors for RA has defined several phases of RA development according to the presence of particular features: genetic and environmental risk factors for RA; autoimmunity associated with RA; symptoms such as joint pain but without clinical arthritis (arthralgia); and clinical arthritis (which can be either unclassified arthritis or RA) 13 . Such observations have encouraged a call for 'preventive trials'; that is, trials that assess treatment initiation in pre-arthritis phases with the ultimate aim of preventing the onset of RA (FIG. 1) .
The challenge of RA prevention raises questions concerning how to accurately identify individuals in the pre-arthritis phases, how to avoid overtreatment and how to manage patients that are presumed to be at risk of developing RA. In this Review, we discuss what is known about the identification of patients at risk of developing RA in different pre-arthritis phases, particularly patients with arthralgia, and the methodological concerns of designing clinical trials that include such patients.
Research into preventive treatment Efficacy of early treatment. At present, all evidence supporting early treatment initiation come from studies of patients with clinically manifest arthritis 2, 14 . Very few trials on treatment initiated in the pre-arthritis phases have been published to date.
Results from studies in experimental animal models of arthritis suggest that providing treatment before arthritis is clinically evident is efficacious. In 2017, a systematic literature review 15 , which included a metaanalysis of 16 such animal model studies, demonstrated that starting immunosuppressive treatment in the induction phase of experimental arthritis (that is, before the development of clinical arthritis and the autoantibody response), has beneficial effects on arthritis severity compared with no treatment. Data was most compelling for methotrexate and abatacept (an inhibitor of T cell co-stimulation). In mice that had autoantibodies but no clinical arthritis, representing a setting in which autoimmunity has developed but not yet clinical arthritis, treatment was also effective. Methotrexate seemed to be more effective than TNF inhibition in this setting, although the different medications were not directly compared in any of the studies included in the meta-analysis 15 . Among the numerous limitations of these experimental studies, two are especially relevant when considering preventive treatment: first, the treatment period in most experiments was extended into the clinical phase and not confined to the pre-arthritis phase, and second, the outcome was arthritis severity and not the development of clinically detectable arthritis. So, although the trends in these animal studies favour the relevance of pre-arthritis treatment, larger studies with treatment confined to the pre-arthritis phase and with head-to-head comparisons of different treatments, such as methotrexate versus abatacept, will yield more information on the preventive effects of DMARDs in experimental models.
The first placebo-controlled trial assessing the initiation of treatment in pre-arthritis in humans was published in 2009 and demonstrated that two intramuscular injections of dexamethasone in seropositive patients with arthralgia decreased autoantibody levels, but did not prevent the development of arthritis 16 . In 2016, results from the PRAIRI (prevention of clinically manifest RA by B cell directed therapy in the earliest phase of the disease) trial demonstrated that a single infusion of rituximab in seropositive patients with arthralgia and any sign of systemic and/or local inflammation delayed, but did not prevent, the development of clinical arthritis 17 (TABLE 1) . Several other proof-of-concept trials are ongoing (TABLE 2) . The study populations and the drugs used vary in the different trials, but in the majority of the trials the presence of RA-related autoantibodies (an indicator of RA-associated autoimmunity) is an inclusion criterion. Publication of the results from these trials over the next decade will increase our understanding of whether such interventions can effectively prevent chronic arthritis and, if so, in which subsets of at-risk individuals.
Until positive results are obtained from any these proof-of-concept studies, no evidence is available to support the use of DMARDs in patients without clinical arthritis, which is in line with published recommendations 1,2 . However, as such patients might already be experiencing pain and functional limitations, prescribing NSAIDs or other pain killers to reduce pain seems logical, as is close monitoring of these patients for the development of clinical arthritis.
The importance of risk stratification. Risk stratification is an essential strategy for advancing research in RA prevention. Adequate risk stratification is crucial when designing and interpreting the results of preventive studies; within the study population, the risk each individual has of developing the disease outcome (such as clinically evident RA) considerably affects the power of the study. The greater the percentage of individuals included in the study that have a low risk of developing RA within 1 or 2 years (known as 'non-informative' inclusions),
Key points
• Early treatment initiation in patients with clinically manifest rheumatoid arthritis (RA) is associated with improved disease outcomes; hence, disease modulation in pre-arthritis phases might prevent the occurrence of clinical arthritis • The inclusion of patients with a low risk of developing RA might dilute possible preventive effects and result in false-negative results in preventive trials • Although a symptomatic phase typically precedes clinical arthritis in patients who develop RA, arthralgia is common and is not specific enough to identify patients at risk of developing RA • The EULAR definition of 'arthralgia suspicious for progression to RA', which identifies patients with arthralgia at risk of developing RA, is a good starting position for preventive trial participant selection • Adequate stratification of patients with arthralgia at risk of developing RA requires a combination of clinical, serological and imaging markers the lower the power of the study. This phenomenon is especially notable in trials with relatively low samples sizes, such as some of the preventive trials performed over the past decade 16, 17 . The importance of risk stratification was illustrated in 2017 in a post hoc analysis of the PROMPT (probable RA: methotrexate versus placebo treatment) trial 18, 19 . In this trial, patients with undifferentiated arthritis were randomly allocated to receive either methotrexate or placebo in order to either prevent the development of RA (the primary outcome) or achieve drug-free remission (the secondary outcome) 18 . Analysis of the whole cohort showed that metho trexate treatment neither prevented RA development nor resulted in drug-free remission. Initial post hoc analysis suggested, however, that methotrexate had a beneficial effect in anti-citrullinated protein antibody (ACPA)-positive patients but not in ACPA-negative patients. Although the ACPA-positive patients had a higher risk of developing RA than ACPA-negative patients, stratifying patients solely on the basis of ACPA status was too simplistic. Previous studies investigating the natural course of undifferentiated arthritis have shown that only one-third of these patients will develop RA, whereas the rest develop different diagnoses or go into spontaneous remission 20, 21 . Hence, investigators subsequently developed and validated a model that predicts the risk of undifferentiated arthritis progressing to RA in an individual patient, taking into account data on clinical features, the presence of rheumatoid factors or ACPAs and levels of C-reactive protein (CRP) 22, 23 . When repeating the analyses of the PROMPT trial considering only those patients predicted to have a high risk of RA by use of this model (>80% probability of progression to RA in the next year; referred to here as 'high-risk' patients), methotrexate was shown to prevent RA development (with an estimated number needed to treat of 2.2) 19 . The PROMPT trial was performed before the development of the 2010 ACR-EULAR classification criteria for RA 24 . Therefore, the secondary outcome, DMARDfree remission, is of importance as this outcome was independent of classification criteria. Interestingly, methotrexate treatment increased the proportion of high-risk patients who achieved DMARD-free remission after 5 years of follow-up (none (0%) of the 11 patients in the placebo group versus four (36%) of the 11 patients in the methotrexate group) 19 . Further stratification of these high-risk patients by ACPA status showed a preventive effect in both ACPA-positive and ACPA-negative patients, whereas no effect was observed in ACPA-positive or ACPA-negative patients at a lower risk of developing RA, indicating that these two latter groups contained predominantly noninformative inclusions. In other words, the previous conclusion that methotrexate might only work in ACPA-positive patients with undifferentiated arthritis was attributable to the fact that this group of patients included a higher proportion of high-risk patients than the group of ACPA-negative patients with undifferentiated arthritis. Altogether, these data highlight the importance of patient stratification: only when studying patients with a high risk of developing RA was the important preventive effect observed. These results are based on post hoc analyses with small numbers of patients, but they underline the relevance of adequate prognostication in prevention trials in order to avoid false-negative trial results. Shared decision-making between physicians and patients requires the physician to adequately inform the patient about their risk of developing RA. In the past 2 years, qualitative studies have revealed that individuals at risk of developing RA have difficulty interpreting their probability of developing RA in the future when it is expressed as a percentage, and that they prefer to receive a 'yes' or 'no' answer to the question of whether they will develop RA 25, 26 . This finding implies that, in discussions with patients in the pre-arthritis phase about whether to initiate treatment, the most appropriate risk-prediction tools to use are those with high positive and negative predictive values (that is, tests with a clear-cut readout).
Translating research into clinical practice also depends on appropriate risk stratification. If the ongoing proof-of-concept studies (TABLE 2) are successful and their results support the treatment of patients with arthralgia in order to prevent clinically apparent arthritis, the next question will concern whom to treat. Insufficient risk stratification of proof-of-concept trial results might result in overtreatment, as patients that are only considered at low risk of developing RA would receive treatment. This overtreatment is highly undesirable, both from the perspective of individual patients and from the socioeconomic point of view. Thus, adequate risk stratification is crucial.
Perceptions of preventive treatment. Interpreting and communicating with patients the risks and benefits of a treatment strategy is complicated, particularly in the setting of preventive trials, as not only is the efficacy and safety of a particular treatment strategy uncertain, so is the baseline risk of the patient population developing RA. Therefore, studies evaluating patient perceptions should include a multidisciplinary team of patients, health professionals and rheumatologists.
The importance of this communication is illustrated by the results of one trial investigating the benefits of personalized risk education; in this trial, those individuals at risk of RA who received personalized risk education, which incorporated factors such as smoking, diet, exercise and dental hygiene, were more motivated to change their health behaviours than individuals who received standard education about RA 27 . A patient's perception of the risks and benefits of preventive treatment can affect their willingness to take such medication. As mentioned above, individuals prefer a yes or no answer on the question of whether they will develop RA [24] [25] [26] . In 2016, a Swiss study evaluated, from the perspective of individuals at risk of developing RA (that is, 32 asymptomatic first-degree relatives (FDR) of patients with RA), what level of risk justifies the initiation of treatment, and which factors influence this decision 28 . Initially, the investigators assigned all participants a hypothetical baseline risk of developing RA. The participants were then presented with hypothetical scenarios, involving potential preventive treatments with a number of attributes of different levels (extent of risk reduction, risk of mild and serious adverse events and mode of administration), and were asked whether they would be willing to take the preventive treatment. Overall, the willingness to take preventive medication increased in parallel with the risk of developing RA: 38% of the FDRs studied would be willing to take medication if the risk of RA was 40%, whereas 30% and 7% would be willing to take preventive medication if the risks of RA were 20% and 1%, respectively. Attribute analyses revealed that the odds of accepting preventive treatment were higher if treatment was associated with a ≥20% reduction in the risk of developing RA compared with treatment that only delayed RA development, and was also higher for treatment associated with a lower risk of serious adverse events (≤10%) compared with a higher risk (>10%). Interestingly, several factors showed no association with willingness to take preventive medication (that is, these factors did not seem to influence an individual's decision), including a delay in the onset of RA (instead of its prevention), a risk of mild adverse events, and the mode of administration of the medication (oral, injection or infusion) 28 . Although larger studies on this subject are needed, as well as studies of individuals considered at risk because of their symptoms rather than because they have a FDR with RA, these data highlight the important influence of patient perceptions on willingness to take preventive medication and the contributing factors that should be taken into account when designing preventive trials and translating findings into clinical practice. Studies in the field of oncology and cardiovascular diseases have shown that adherence to preventive medications is rather poor and hence the willingness of patients to take such medication is of utmost importance 29, 30 .
RA prevention in clinical practice
Disease prevention in different healthcare settings. Disease prevention includes a wide range of procedures and interventions, all aimed at reducing the risks and threats to patient health. Primary, secondary and tertiary prevention are different in nature 31 (FIG. 2) . Primary prevention aims to prevent disease before it occurs and can be directed at either the whole population, individuals at high risk of disease as a result of a particular factors (for example, individuals with specific genetic risk factors or individuals that smoke) or individuals of a specific age or sex. Examples of primary prevention are the immunization of young children and the screening and treatment of hypertension in a high-risk population (for example, individuals predicted to be at high risk based on their age, BMI and/or ethnicity) to prevent future cardiovascular events. Screening for the presence of certain serological factors (for example, RA-related autoantibodies) in the general population or in the FDRs of patients with RA, who have a threefold to fourfold increased risk of developing RA, can be considered to be relevant to primary intervention. Despite the increased risk of disease development in family members of patients with RA, the absolute risk in such individuals is low, as is the absolute risk of an asymptomatic individuals in the general population developing disease [32] [33] [34] . However, the features of primary prevention are outside the scope of this Review, and are not discussed further. , in relation to the possible types of prevention (primary, secondary or tertiary). In addition, it illustrates the risk of RA development for different groups of individuals identified in different settings, and the relative sizes of these groups. Not all patients will pass through every phase of RA development and some phases can be present at the same time (for example, smoking, autoimmunity and arthralgia). FDR, first-degree relative; CSA, clinically suspect arthralgia; MSK, musculoskeletal; UA, undifferentiated arthritis. Secondary prevention aims to reduce the symptoms of a disease that has already occurred, such as joint pain. This process involves detecting and treating the disease as soon as possible to halt (or slow) disease progression. An example of secondary prevention is the regular screening of women over the age of 50 years for breast cancer by mammography. Although the phase in which RA starts is not completely clear, interventions performed in the symptomatic phase of arthralgia (the phase preceding clinical synovitis) can be considered a form of secondary prevention (FIG. 2) . Tertiary prevention aims to mitigate the effects of an ongoing disease; in the case of RA, tertiary prevention concerns patients with clinical arthritis and/or RA, which is also beyond the scope of this Review.
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In the context of RA, intervention aimed at secondary prevention begins with the identification of patients with arthralgia who might progress to RA. However, not all patients with arthralgia are similar, and the balance of whether or not to screen and/or treat a patient with arthralgia will depend on the pretest probability that a patient has an inflammatory form of arthralgia; this probability can vary depending on the health care setting (as discussed below).
Identifying patients at risk of developing RA.
Patients at risk of developing RA can be identified by different approaches depending on the health care setting (FIG. 2) . Screening for patients with arthralgia and secondary intervention can be performed in a primary (the general practice surgery) or secondary (the rheumatology outpatient clinic) health care setting. In primary care, interventions can be performed on all patients that present with any type of musculoskeletal symptoms. Although the exact numbers of individuals with musculo skeletal symptoms are unknown, such symptoms are a common complaint in primary care. However, for the vast majority of these patients, their symptoms will be unrelated to (imminent) RA and, although the exact numbers are unknown, the proportion of these patients that have suspected arthritis is probably small. In the United Kingdom, patients with RA have been reported to visit their general practitioner up to eight times before being referred to secondary care 35 ; nonetheless, patients with (imminent) RA comprise a very small proportion of all patients visiting general practitioners 36 . Only some patients with any form of musculo skeletal symptoms are referred to secondary care, as these patients are generally only referred if the general practitioner judges that they have a high pretest probability of developing an inflammatory disease. Although referral criteria have been proposed for identifying patients with suspected early RA, such as the presence of metatarsophalangeal and/or metacarpophalangeal involvement and morning stiffness lasting ≥30 minutes 37 , most general practitioners differentiate patients using their expertise. Although fewer patients with musculoskeletal symptoms visit secondary care than primary care, this population is still heterogeneous. Patients with either clinical arthritis or evident RA represent only a small proportion of those patients with musculoskeletal symptoms that are referred to secondary care 38 . Similarly, only a small proportion of these patients are considered to have clinically suspect arthritis (CSA; that is, patients with arthralgia without clinical arthritis but considered to be at risk of developing RA on the basis of their clinical presentation) 38 . A Dutch observational study showed that patients with CSA comprised only 6.5% of all patients that presented to rheumatologic care without clinical arthritis and with arthralgia that was otherwise unexplained 39 . In secondary care, pattern recognition and clinical expertise are important for differentiating patients with arthralgia who are at risk of developing RA from patients with other types of arthralgia.
In other words, not all patients with arthralgia are similar and the probability of a patient with arthralgia subsequently developing RA varies depending on the setting from which the patient is selected (FIG. 2) . Patients with CSA, who have a higher probability of developing RA than a typical patient with arthralgia, constitute only a small subgroup of patients with arthralgia presenting in secondary care 37 . Importantly, a study in 2016 reported that clinical expertise (that is, the judgement that a patient has CSA) has a high sensitivity for identifying at-risk patients in secondary care (80%), and that few patients who present with arthralgia that later progress to RA are missed by their rheumatologists 38 . Although clinical expertise is regularly used in daily care, its subjectivity is an obvious drawback for scientific studies. Hence, a EULAR task force set out to explicate this particular clinical expertise in defined measurable terms and reached a definition for 'arthralgia suspicious for progression to RA' (REF. 40 ). This definition is intended to be used in secondary care in patients with arthralgia considered by the rheumatologist more likely to be imminent RA than other diagnoses (that is, patients with CSA). The clinical definition consists of seven items, five of which are obtained by history taking and two by physical examination
. Health care systems around Box 1 | EULAR definition of arthralgia suspicious for progression to RA 38 A sensitive definition of arthralgia suspicious for progression to rheumatoid arthritis (RA) requires the presence of at least three of the seven items listed below*. A specific definition requires the presence of at least four of these items. This definition is designed to be used in patients with arthralgia without clinical arthritis and without another explanation for the arthralgia. 
Physical examination
• Difficulty with making a fist • Positive squeeze test of metacarpophalangeal joints *The reported area under the curve (AUC) of this combination of parameters is 0.93. The sensitivity and specificity of this combination of parameters in the presence of three or more items are 90% and 74%, respectively. These values were calculated in a validation study with the clinical expertise of a group of European expert rheumatologist that evaluated patients in their own practices as reference 40 the world are organized differently, with primary care being managed either by general practitioners or by specialists (such as internists, gynaecologists, orthopaedists or surgeons), resulting in different populations of patients with arthralgia. However, all these health care systems have rheumato logists who see patients with suspected imminent RA and, therefore, the EULAR definition of arthralgia suspicious for progression to RA is applicable in almost all health care systems. The aim of this definition is to harmonize what group of patients rheumatologists consider being at risk of developing RA. Indeed, data have revealed that this definition serves well to exclude some patients that (despite a rheumatologist's suspicion of imminent RA) actually have a low risk of RA. Additionally, the application of this definition in patients with CSA identified a subgroup of patients with a slightly higher risk of subsequent RA compared with the remaining patients with CSA 41 . In conclusion, selecting patients with arthralgia and a high risk of developing RA, such as patients who fulfil the EULAR definition of arthralgia suspicious for progression to RA, might offer an optimal starting position from which to investigate the mechanisms underlying this phase of RA development or to design preventive trials.
Predicting disease risk in different health care settings. Selecting the correct subgroup of individuals to test (risk stratification) is essential as this selection can influence the post-test probability of the tested population developing RA. This general principle is exemplified when considering ACPA status as a predictive indicator of RA development (TABLE 3) . In the general population, the risk of ACPA-positive individuals developing RA over 5 years is estimated to be ~5%, with a lifetime risk of 16% 6, 7 . The prevalence of ACPA-positive individuals in the general population is 1-2% [42] [43] [44] , and the results from a longitudinal study in this setting suggest that the presence of ACPAs in symptom-free individuals is associated with an 8.5% risk of developing RA after ~3 years of follow-up 42 . These findings mean that 91.5% of ACPA-positive individuals will not develop RA in the forthcoming years (and hence these patients will have false-positive diagnoses when ACPA status is used as a measure for predicting RA development).
Based on the prevalence of ACPA-positive individuals and the positive predictive value (PPV) of ACPA testing in the general population, the number of individuals in the general population that need be to tested in order to identify one patient who will develop RA can be estimated at ~1,200.
Several studies on ACPA-positive arthralgia have been performed in different settings (health fairs, primary care or secondary care, or combinations thereof) [45] [46] [47] . In these studies, the PPV of ACPA testing for RA development over 1 year ranged from 20% to 34% 45, 46, 48 . As the number of individuals that underwent ACPA testing was not reported, the number needed to test (NNT) in order to identify a patient that will progress onto developing RA cannot be estimated. 16% of patients with CSA are estimated to be ACPApositive 11 , and a positive ACPA test in such patients is associated with a 63% risk of developing clinical arthritis within 1 year; thus, in this subset of patients the risk of a false-positive test result, when using ACPA status as a predictor of arthritis development within 1 year, is 37%. Based on these data, the number of patients with CSA that need to be tested to identify one ACPA-positive patient who develops RA within 1 year is ten. Hence, the higher the a priori risk of developing RA, the higher the predictive value of ACPA testing for subsequent RA development (that is, the higher the PPV and the lower the risk of false-positivity) and thus the lower the NNT to identify one patient who will develop RA (TABLE 3) . It is hoped that incorporating measurements of other structural features of ACPA, such as the presence of specific glycans in the Fab or Fc domain of ACPA molecules, will lead to better performance of ACPA assays 49, 50 .
Identifying imminent RA. Knowledge of ACPA status alone is insufficient to accurately stratify patients with arthralgia who are clinically at risk of developing RA (that is, patients with CSA), as the PPV of ACPA testing is at most 63% 11 (implying that ≥37% of ACPA-positive patients would have false-positive diagnoses), and up to half of the patients with newly diagnosed RA are ACPA-negative and hence are missed by this approach (false-negatives). Patients prefer tests that have a very high PPV (that is, a test that can confirm or exclude imminent RA). Hence, additional ways of stratifying patients are needed. For patients presenting with musculoskeletal symptoms in primary care, and unselected patients with musculoskeletal symptoms in secondary care, the prevalence of ACPA, the PPV of ACPA testing of such patients and the NNT to identify one patient who will develop RA is unknown. *Estimated PPV based on the number of ACPA-positive individuals who developed RA in the specified period. ‡ Estimated NNT based on the prevalence and PPV; in the setting of the general population, the calculation was performed with a prevalence of 1%. ACPA, anti-citrullinated peptide antibody; CSA, clinically suspect arthralgia; NNT, number needed to test; PPV, positive predictive value; RA, rheumatoid arthritis.
Studies have identified other potential biomarkers for predicting RA progression. For example, subclinical joint inflammation, detected either by MRI or by ultrasonography, is a proven predictive indicator of RA development [9] [10] [11] 51 . Further studies are required that directly compare the predictive accuracy of both imaging modalities, and that evaluate the minimal region needed to be imaged for maximal results; however, current data demonstrate that subclinical inflammation can predict RA development independently of autoantibody status and clinical features in patients with CSA, indicating that the presence of both autoantibodies and subclinical inflammation might further increase the risk of developing RA compared with the presence of each feature alone 10, 11 . Increased levels of CRP can also independently predict RA development in such patients 11 . Finally, preliminary studies investigating the predictive value of certain B cell or T cell characteristics, as well as of gene expression profiles in whole blood, have shown promise [52] [53] [54] [55] [56] . Although these studies require replication, these markers are of interest as they might provide further insight into the aetiopathogenetic mechanisms of RA.
Several ongoing studies are investigating other predictors of RA development, such as autoantibodies other than ACPAs and structural features of autoantibodies; these studies include not only patients with arthralgia but also asymptomatic FDRs of patients with RA, in an attempt to look at individuals with a higher likelihood of developing RA than the general population [57] [58] [59] [60] . Together these studies might provide additional information on RA development and help with the prediction of RA development in different at-risk populations.
Three separate studies have combined different types of predictors in patients with arthralgia to develop a prediction model. Unfortunately, these studies investigated different patient populations (ACPA-positive patients with nonspecific musculoskeletal symptoms in primary care, autoantibody-positive patients with arthralgia, and patients with CSA in secondary care) and so cannot be directly compared 11, 45, 46 . Although the results were promising, none of these models has yet been validated in independent patient populations. So, although information on different types of biomarkers are available, the use of different patient populations in these studies, in all of which the risk of developing RA is different, hampers the validation of each biomarker and/or model.
Several outstanding questions remain to be addressed when examining disease progression from arthralgia to arthritis
. In order to be able to accurately predict RA development from the pre-arthritis phases, researchers should collaborate and use similar criteria (such as the EULAR definition of arthralgia suspicious for progression to RA) for evaluating clinically relevant patient groups. The harmonization of patient selection will enable researchers to combine the results of studies performed at different centres and to assess and/or validate findings from other centres. Furthermore, more extensive observational studies on the natural course of arthralgia in patients at risk of developing RA (without DMARD treatment) are needed to improve risk stratification. This research could reveal whether physicians should initiate preventive treatment and, if so, in which groups of patients.
Conclusions
The development of RA is a multistep process that can be ongoing for years before arthritis is present. Prearthritis phases might be part of the therapeutic window of opportunity and disease modulation during this phase is hypothesized to prevent clinically apparent and persistent RA from arising. To examine whether progression from arthralgia to arthritis can be prevented, correctly identifying patients (that is, accurate risk prediction) is crucial, and should overcome false-negative study results. Currently, several different approaches for For the design and interpretation of preventive studies, and translating such findings into clinical practice, several questions remain to be addressed:
• Is it possible to predict with a high accuracy (for example, a positive predictive value of ≥80%) which patients with arthralgia will develop rheumatoid arthritis (RA), using symptoms, clinical signs and additional tests that are feasible to implement in clinical practice? And if so, how? • Will any primary care tool(s) be able to identify patients with a high risk of developing arthritis and/or future RA, who should hence be referred to rheumatologic care? And if so, which ones? • What biologic processes are responsible for the development of arthralgia and subclinical inflammation and which processes determine whether these features are progressive or will resolve spontaneously? • What are the overlapping and non-overlapping pathways that contribute to the development of anti-citrullinated peptide antibody (ACPA)-positive and ACPA-negative RA? • Can the development of clinically apparent persisting arthritis be prevented by treating patients in the symptomatic pre-arthritis phase (or does disease maturation occur at an earlier stage)? • If proof-of-concept trials reveal beneficial effects of initiating treatment in the pre-arthritis phase, which drugs are most effective (and in which subset of patients)? And for how long should patients be treated to prevent RA development? • What is an acceptable 'number needed to test' for tests that identify patients with RA in pre-arthritis stages?
• What is an acceptable 'number needed to treat' to prevent RA development?
• What personal and social factors determine a patient's willingness to start preventive treatment and adhere to such treatment?
identifying at-risk populations are being tested and several trials are ongoing. However, whether disease modulation in the pre-arthritis phase has beneficial effects has not yet been demonstrated. Refining the term arthralgia and specifying the clinical characteristics of patients who have arthralgia and are at risk of developing RA, such as the EULAR definition of arthralgia at risk for RA, might reduce the heterogeneity of patients included in different studies. The EULAR definition is a sensitive predictor of RA development, and reflects expert opinion of imminent RA 41 . Therefore, this definition might offer an optimal starting position for investigating the mechanisms underlying this phase of RA development and designing preventive trials. Further research is needed to characterize the evolution from pre-arthritis to clinically overt disease in order to establish if disease modulation in this phase is effective in preventing RA (and if so, with which drugs).
